FindTrial
Sign In

To test the disease free survival (DFS) prediction ability of the OncoDiscover diagnostic technology â?? a simple liquid biopsy blood test for cancer patients.

A prospective observational clinical trial with case control study design to test the prognostic ability of a proprietary OncoDiscoverTM diagnostic technology designed to capture and concentrate circulating tumor cells (CTCs) in blood samples of patients with various carcinomas and its use to predict progression free survival (PFS) and disease free survival (DFS). (PROGCTC)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/04/012920
Enrollment
300
Registered
2018-04-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Quasi-metastatic patients (stage II & stage III) suffering from the breast, colo-rectal, cervical, ovarian, esophageal / stomach and loco-regional (oral, larynx, tongue, head & neck etc.) cancers

Interventions

None listed

Sponsors

Actorius Innovations and Research Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Quasi-metastatic patients (stage II & stage III) suffering from the breast, colo-rectal, cervical, ovarian, esophageal / stomach and loco-regional (oral, larynx, tongue, head & neck etc.) cancers would be considered for the aforementioned trial. 2. Males (lung, colorectal, esophageal, stomach, loco-regional) and/or females (Breast, ovarian, cervical, colorectal, esophageal, stomach, loco-regional). 3. Patients who are yet to receive the treatment. 4. Age > 18 years. 5. Patients who are well counselled about the trial and from who written informed consent obtained. 6. Confirmed diagnosis of Stage II or III cancer by oncologist. 7. Able to undergo blood collection after diagnosis and prior to surgery and initiation of the therapy, 8. Those patients, who would provide the blood sample after diagnosis, surgery and at the initiation, in the course of and at the end of the treatment.

Exclusion criteria

Exclusion criteria: 1. Patients unable to understand the research protocol and/or provide informed consent. 2. Patients with known immunodeficiency, or pregnancy. 3. Participation in another cancer screening trial.

Design outcomes

Primary

MeasureTime frame
Ability of diagnostic technology for evaluation of CTC to predict PFS and DFS in patients suffering from breast, colorectal, esophageal / stomach, cervical, ovarian and loco-regional cancers. [Time Frame: 36 months].Timepoint: 36 months—

Secondary

MeasureTime frame
Agreement between CTC counts (3-4 weeks and 6-8 weeks) after the initiation of a new line of systemic therapy and the patients response as determined by CTC evaluation). [ Time Frame: 12 months] To correlate the data generated with TNM staging. [12 months]Timepoint: 12 months—

Countries

India

Contacts

Public ContactAravindan Vasudevan

Actorius Innovations and Research Pvt Ltd

jayant@actorius.co.in9920526627

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026